glp-1 options for type 2 diabetes and obesity 2025 Many adults stop therapy within a year with low restart rates, analysis finds Nutritional priorities to support GLP-1

Appetite changes typically appear within two to four weeks

M.UbahC

Gastrointestinal symptoms, particularly nausea and diarrhea, affected a higher percentage of trial participants

Book Now Browse our full library of evidence-based weight loss resources

49 GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients and potentially hold promise in addressing other medical conditions

The doctor will consider several aspects of your health and wellness before deciding whether Semaglutide GLP-1 treatment is the best approach to weight loss in your case